Mark K Farrugia1, Malcolm D Mattes2. 1. Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm St, Buffalo, NY, 14203 USA. 2. Department of Radiation Oncology, West Virginia University, 1 Medical Center Dr, Morgantown, WV 26505, USA.
Abstract
OBJECTIVE: Patients undergoing prostate radiation therapy were observed to have elevated blood pressures in clinic. Therefore, we sought to further characterise this phenomenon. METHODS: The charts of 76 patients who received radiotherapy for prostate cancer between 2014 and 2017 were examined. Blood pressure (BP) readings were obtained at initial consultation, on treatment visits, and subsequent follow-up appointments. To describe this effect, we defined radiation-associated hypertension (RAH) as an increase ≥15 mmHg systolic BP, 10 mmHg diastolic BP, or 5 mmHg mean arterial pressure. RESULTS: Within this cohort, 36 patients developed RAH, with 75% developing RAH while on treatment, and 25% developing RAH at post-treatment visits. Two-thirds of patients remained hypertensive during post-treatment visits, and 27% were prescribed additional anti-hypertensives. There was no association between neoadjuvant/concurrent androgen deprivation therapy and RAH. CONCLUSION: A significant number of patients undergoing prostate radiotherapy developed RAH, necessitating additional medication in some.
OBJECTIVE: Patients undergoing prostate radiation therapy were observed to have elevated blood pressures in clinic. Therefore, we sought to further characterise this phenomenon. METHODS: The charts of 76 patients who received radiotherapy for prostate cancer between 2014 and 2017 were examined. Blood pressure (BP) readings were obtained at initial consultation, on treatment visits, and subsequent follow-up appointments. To describe this effect, we defined radiation-associated hypertension (RAH) as an increase ≥15 mmHg systolic BP, 10 mmHg diastolic BP, or 5 mmHg mean arterial pressure. RESULTS: Within this cohort, 36 patients developed RAH, with 75% developing RAH while on treatment, and 25% developing RAH at post-treatment visits. Two-thirds of patients remained hypertensive during post-treatment visits, and 27% were prescribed additional anti-hypertensives. There was no association between neoadjuvant/concurrent androgen deprivation therapy and RAH. CONCLUSION: A significant number of patients undergoing prostate radiotherapy developed RAH, necessitating additional medication in some.
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano Journal: J Endocrinol Invest Date: 2013-02 Impact factor: 4.256
Authors: Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder Journal: BJU Int Date: 2008-12 Impact factor: 5.588
Authors: Jian Guan; Jay Khambhati; Lee W Jones; Alicia Morgans; Mohamad Allaf; David F Penson; Javid Moslehi Journal: Circulation Date: 2015-11-03 Impact factor: 29.690
Authors: Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli Journal: Mayo Clin Proc Date: 2014-09 Impact factor: 7.616